Grifols SA history, profile and history video
Grifols SA operates as a fractionator of plasma derived blood products. The company operates through four segments: Bioessence, Hospital, Diagnostic and Raw Materials. The Bioessence segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by Group companies earmarked for hospital pharmacy. The Diagnostic segment includes the marketing of diagnostic testing equipment, reagents, and other equipment. The Raw Materials segment includes the sale of intermediate biological products and the rendering of manufacturing services to third party companies. The company applies sophisticated science and technology to improve people’s health and well-being through providing life-saving products. The company was founded on June 22, 1987 and is headquartered in Barcelona, Spain.“
Grifols was founded in 1940 in Barcelona by Dr José A. Grifols Roig, a hematologist and scientist. Dr Grifols was the first researcher to publish the plasmapheresis procedure in 1951. The company introduced its liquid IVIG product into the European market in the mid-1990s. In 2003 the company acquired certain assets of the Los Angeles-based Alpha Therapeutic as the basis of its American expansion.
On June 1, 2011, a year after announcing the $4 billion deal, Grifols completed a takeover of Talecris Biotherapeutics, headquartered in Research Triangle Park in North Carolina, with over 2000 employees.
Grifols acquired the blood transfusion diagnostics unit from Novartis in 2013 as a “platform for global expansion”. This unit is based in Emeryville, California and was a part ofChiron acquired by Novartis in 2006.”
*Information from Forbes.com and Wikipedia.org
**Video published on YouTube by “La Resistencia”